176 related articles for article (PubMed ID: 16550720)
1. Acromegaly: effects on bone metabolism and mass.
Bogazzi F; Cosci C; Sardella C; Martino E; Gasperi M
J Endocrinol Invest; 2005; 28(10 Suppl):33-5. PubMed ID: 16550720
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender.
Tütüncü NB; Erbaş T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):328-32. PubMed ID: 15216451
[TBL] [Abstract][Full Text] [Related]
3. Rheumatologic and skeletal changes in acromegaly.
Lieberman SA; Björkengren AG; Hoffman AR
Endocrinol Metab Clin North Am; 1992 Sep; 21(3):615-31. PubMed ID: 1521515
[TBL] [Abstract][Full Text] [Related]
4. Somatopause: dismetabolic and bone effects.
Lombardi G; Tauchmanova L; Di Somma C; Musella T; Rota F; Savanelli MC; Colao A
J Endocrinol Invest; 2005; 28(10 Suppl):36-42. PubMed ID: 16550721
[TBL] [Abstract][Full Text] [Related]
5. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
Zgliczynski W; Kochman M; Misiorowski W; Zdunowski P
Neuro Endocrinol Lett; 2007 Oct; 28(5):621-8. PubMed ID: 17984937
[TBL] [Abstract][Full Text] [Related]
6. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study.
Battista C; Chiodini I; Muscarella S; Guglielmi G; Mascia ML; Carnevale V; Scillitani A
Clin Endocrinol (Oxf); 2009 Mar; 70(3):378-82. PubMed ID: 18616713
[TBL] [Abstract][Full Text] [Related]
7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
8. The GH-IGF-I axis and the cardiovascular system: clinical implications.
Colao A
Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
[TBL] [Abstract][Full Text] [Related]
9. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
[TBL] [Abstract][Full Text] [Related]
10. Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly.
Madeira M; Neto LV; de Lima GA; Moreira RO; de Mendonça LM; Gadelha MR; Farias ML
Osteoporos Int; 2010 Dec; 21(12):2019-25. PubMed ID: 20306022
[TBL] [Abstract][Full Text] [Related]
11. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
Bielohuby M; Roemmler J; Manolopoulou J; Johnsen I; Sawitzky M; Schopohl J; Reincke M; Wolf E; Hoeflich A; Bidlingmaier M
Exp Biol Med (Maywood); 2009 Aug; 234(8):1002-9. PubMed ID: 19491373
[TBL] [Abstract][Full Text] [Related]
12. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly.
Jockenhövel F; Rohrbach S; Deggerich S; Reinwein D; Reiners C
Eur J Med Res; 1996 May; 1(8):377-82. PubMed ID: 9360937
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cognitive performance by using P300 auditory event related potentials (ERPs) in patients with growth hormone (GH) deficiency and acromegaly.
Tanriverdi F; Yapislar H; Karaca Z; Unluhizarci K; Suer C; Kelestimur F
Growth Horm IGF Res; 2009 Feb; 19(1):24-30. PubMed ID: 18567522
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.
Bolanowski M; Daroszewski J; Medraś M; Zadrozna-Sliwka B
J Bone Miner Metab; 2006; 24(1):72-8. PubMed ID: 16369902
[TBL] [Abstract][Full Text] [Related]
15. Regulation of bone mass by growth hormone.
Olney RC
Med Pediatr Oncol; 2003 Sep; 41(3):228-34. PubMed ID: 12868124
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
Wiesli P; Zwimpfer C; Zapf J; Schmid C
Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
[TBL] [Abstract][Full Text] [Related]
17. The role for growth hormone in linking arthritis, osteoporosis, and body composition.
Tauchmanova L; Di Somma C; Rusciano A; Lombardi G; Colao A
J Endocrinol Invest; 2007; 30(6 Suppl):35-41. PubMed ID: 17721072
[TBL] [Abstract][Full Text] [Related]
18. Biochemical evidence supporting the Cortina criteria.
von Werder K
J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
[TBL] [Abstract][Full Text] [Related]
19. Circulating cytokines in relation to bone mineral density changes in patients with acromegaly.
Bolanowski M; Daroszewski J; Zatonska K; Arkowska A
Neuro Endocrinol Lett; 2006; 27(1-2):183-8. PubMed ID: 16648806
[TBL] [Abstract][Full Text] [Related]
20. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
